The legal marijuana industry has demonstrated explosive growth in recent years, and marijuana stock investors are taking notice.
A report from ArcView Market Research, which was released last year, shows that more than $46 billion of the $53.3 billion in North American legal pot sales last year were conducted under the table. Some might view this as a major loss for the pot industry, but AGRiMED/SATIVEO/UNVC does not worry about such things because they compete in the medical marijuana industry, and in the emerging HEMP industry.
Let’s take at AGRiMED/SATIVEO/UNVC. So far, their entire pipeline is dependent on cannabinoid-based products, and they have two product candidates in the pipeline. The first product is the transdermal patch originally developed by Univec in 2012 for nicotine replacement therapy. At that time the FDA approved the Univec patch and granted them National Drug Codes to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery systems, and is a foundation to build and grow on. However, Univec never did market this product. Enter AGRiMED.
On October 2, 2017 — AGRiMED, which owns one of the twelve licenses authorized by the Commonwealth of Pennsylvania to grow and process medical cannabis, announced a unique and innovative partnership with Univec, Inc (UNVC), a specialty pharmaceutical company to manufacture and distribute its medical cannabis transdermal patch for treatment and relief of approved medical conditions. The transdermal patch adheres to the skin and delivers a specific and controlled dose of medication through the skin and into the bloodstream.
At that time Sterling Crockett a founder and AGRiMED Industries Chief Executive Officer (CEO) said, “Today’s announcement is consistent with our philosophy of connecting those in need with innovations that heal cleanly, comfortably and sustainably.” He added, “We are excited about working with Univec and look forward to sharing the benefits of this partnership with the people of Pennsylvania and beyond.”
Keep in mind, it was AGRiMED that made the above announcement, and not Univec. This announcement confirms the partnership, and speaks glowing about the relationship with Univec.
Dr. David Dalton, Univec’s CEO said “Combining Univec’s medical and pharmaceutical expertise with AGRiMED Industries’ innovative approach to the cannabis marketplace and commitment to its patient focused services makes for a very powerful partnership to expand the treatment options available to the medical community.”
What I find interesting about this partnership is that the original agreement talked about cannabis oil, but later on AGRiMED’s twitter page, they elaborated on this partnership and specifically mentioned gel as well. In my opinion, a cannabis gel would likely allow for extended medical relief and incorporate additional treatments.
https://agrimedindustries.com/2017/10/04/agri...ip-univec/
A report from ArcView Market Research, which was released last year, shows that more than $46 billion of the $53.3 billion in North American legal pot sales last year were conducted under the table. Some might view this as a major loss for the pot industry, but AGRiMED/SATIVEO/UNVC does not worry about such things because they compete in the medical marijuana industry, and in the emerging HEMP industry.
Let’s take at AGRiMED/SATIVEO/UNVC. So far, their entire pipeline is dependent on cannabinoid-based products, and they have two product candidates in the pipeline. The first product is the transdermal patch originally developed by Univec in 2012 for nicotine replacement therapy. At that time the FDA approved the Univec patch and granted them National Drug Codes to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery systems, and is a foundation to build and grow on. However, Univec never did market this product. Enter AGRiMED.
On October 2, 2017 — AGRiMED, which owns one of the twelve licenses authorized by the Commonwealth of Pennsylvania to grow and process medical cannabis, announced a unique and innovative partnership with Univec, Inc (UNVC), a specialty pharmaceutical company to manufacture and distribute its medical cannabis transdermal patch for treatment and relief of approved medical conditions. The transdermal patch adheres to the skin and delivers a specific and controlled dose of medication through the skin and into the bloodstream.
At that time Sterling Crockett a founder and AGRiMED Industries Chief Executive Officer (CEO) said, “Today’s announcement is consistent with our philosophy of connecting those in need with innovations that heal cleanly, comfortably and sustainably.” He added, “We are excited about working with Univec and look forward to sharing the benefits of this partnership with the people of Pennsylvania and beyond.”
Keep in mind, it was AGRiMED that made the above announcement, and not Univec. This announcement confirms the partnership, and speaks glowing about the relationship with Univec.
Dr. David Dalton, Univec’s CEO said “Combining Univec’s medical and pharmaceutical expertise with AGRiMED Industries’ innovative approach to the cannabis marketplace and commitment to its patient focused services makes for a very powerful partnership to expand the treatment options available to the medical community.”
What I find interesting about this partnership is that the original agreement talked about cannabis oil, but later on AGRiMED’s twitter page, they elaborated on this partnership and specifically mentioned gel as well. In my opinion, a cannabis gel would likely allow for extended medical relief and incorporate additional treatments.
https://agrimedindustries.com/2017/10/04/agri...ip-univec/
1
